Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Merus B V currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners but remain within 1 distinct art unit. Francesca Edgingtongiordano is identified as the busiest examiner, responsible for 1 pending office action.
This structure shows that while the company interacts with multiple examiners, its current prosecution is concentrated within a specific art unit. The presence of 2 pending office actions indicates an active but administratively focused patent portfolio in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16870715 | VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND SEPARATION THEREOF | EDGINGTONGIORDANO, FRANCESCA | 30d |
| 16499723 | ANTIBODIES FOR THE TREATMENT OF ERBB-2/ERBB-3 POSITIVE TUMORS | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16870715 | VARIANT DOMAINS FOR MULTIMERIZING PROTEINS AND SEPARATION THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103 | Non-Final OA | 30d | Pending | May 08, 2020 |
| 16499723 | ANTIBODIES FOR THE TREATMENT OF ERBB-2/ERBB-3 POSITIVE TUMORS | BRISTOL, LYNN ANNE | 1643 | §103Other | Non-Final OA | — | Pending | Sep 30, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial